Patents by Inventor Edward I. Ginns
Edward I. Ginns has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 10143684Abstract: Methods for treating and diagnosing psychiatric affective disorders, e.g., an affective disorder associated with aberrant Sonic Hedgehog (Shh) signaling, by administering to the subject a therapeutically effective amount of an antagonist to Smoothened (Smo), an antagonist to Patched-1 (Ptch-1) and/or an antagonist to Shh.Type: GrantFiled: September 23, 2015Date of Patent: December 4, 2018Assignees: University of Massachusetts, University of MiamiInventors: Edward I. Ginns, Marzena Galdzicka, Janice A. Egeland
-
Publication number: 20140350066Abstract: In certain preferred embodiments, the present invention provides compositions and methods for the treatment of bone conditions associated with low bone density. In preferred embodiments, the present invention provides compositions and methods for the treatment of osteoprotegerin-responsive conditions.Type: ApplicationFiled: November 27, 2013Publication date: November 27, 2014Applicant: UNIVERSITY OF MASSACHUSETTSInventors: Edward I. GINNS, Gary R. OSTROFF
-
Patent number: 8637045Abstract: The present invention provides a therapeutic delivery system comprising an extracted yeast cell wall comprising beta-glucan, a payload trapping molecule and a payload molecule, wherein the payload molecule and the payload trapping molecule are soluble in the same solvent system wherein the payload molecule supplements the function of the deficient lysosomal enzyme. The invention further provides methods of making and methods of using the therapeutic delivery system.Type: GrantFiled: July 29, 2011Date of Patent: January 28, 2014Assignee: University of MassachusettsInventors: Edward I. Ginns, Gary R. Ostroff
-
Publication number: 20130065941Abstract: In certain preferred embodiments, the present invention provides compositions and methods for the treatment of bone conditions associated with low bone density. In preferred embodiments, the present invention provides compositions and methods for the treatment of osteoprotegerin-responsive conditions.Type: ApplicationFiled: August 13, 2012Publication date: March 14, 2013Applicant: UNIVERSITY OF MASSACHUSETTSInventors: Edward I. GINNS, Gary R. OSTROFF
-
Publication number: 20120270206Abstract: The invention relates to systems and methods for analyzing clinically relevant nucleic acid sequences.Type: ApplicationFiled: December 27, 2011Publication date: October 25, 2012Applicant: UNIVERSITY OF MASSACHUSETTSInventors: Edward I. Ginns, Marzena Galdzicka
-
Publication number: 20120039929Abstract: The present invention provides a therapeutic delivery system comprising an extracted yeast cell wall comprising beta-glucan, a payload trapping molecule and a payload molecule, wherein the payload molecule and the payload trapping molecule are soluble in the same solvent system wherein the payload molecule supplements the function of the deficient lysosomal enzyme. The invention further provides methods of making and methods of using the therapeutic delivery system.Type: ApplicationFiled: July 29, 2011Publication date: February 16, 2012Applicant: University of MassachusettsInventors: Edward I. Ginns, Gary R. Ostroff
-
Patent number: 8007814Abstract: The present invention provides a therapeutic delivery system comprising an extracted yeast cell wall comprising beta-glucan, a payload trapping molecule and a payload molecule, wherein the payload molecule and the payload trapping molecule are soluble in the same solvent system wherein the payload molecule supplements the function of the deficient lysosomal enzyme. The invention further provides methods of making and methods of using the therapeutic delivery system.Type: GrantFiled: September 19, 2005Date of Patent: August 30, 2011Assignee: University of MassachusettsInventors: Edward I. Ginns, Gary R. Ostroff
-
Patent number: 7939310Abstract: The invention relates to systems and methods for analyzing clinically relevant nucleic acid sequences.Type: GrantFiled: August 6, 2004Date of Patent: May 10, 2011Assignee: University of MassachusettsInventors: Edward I. Ginns, Marzena Galdzicka
-
Publication number: 20090209624Abstract: In certain preferred embodiments, the present invention provides compositions and methods for the treatment of bone conditions associated with low bone density. In preferred embodiments, the present invention provides compositions and methods for the treatment of osteoprotegerin-responsive conditions.Type: ApplicationFiled: October 24, 2006Publication date: August 20, 2009Applicant: University of MassachusettsInventors: Edward I. Ginns, Gary R. Ostroff
-
Patent number: 6897022Abstract: Chromosomal regions comprising loci associated with susceptibility and resistance to bipolar affective disorder have been identified. Methods and compositions are provided for determining the contribution of these chromosomal regions to bipolar affective disorder in an affected family, for determining in an affected family a genotype associated with increased or decreased susceptibility or resistance to bipolar illness, and for assessing an increased or decreased risk of developing bipolar illness for a tested individual from an affected family.Type: GrantFiled: June 13, 2001Date of Patent: May 24, 2005Assignees: University of Miami, The United States of America as represented by the Secretary of Health & Human ServicesInventors: Edward I. Ginns, Janice A. Egeland, Steven M. Paul
-
Publication number: 20040248086Abstract: Chromosomal regions comprising loci associated with susceptibility and resistance to bipolar affective disorder have been identified. Methods and compositions are provided for determining the contribution of these chromosomal regions to bipolar affective disorder in an affected family, for determining in an affected family a genotype associated with increased or decreased susceptibility or resistance to bipolar illness, and for assessing an increased or decreased risk of developing bipolar illness for a tested individual from an affected family.Type: ApplicationFiled: June 13, 2001Publication date: December 9, 2004Inventors: Edward I. Ginns, Janice A. Egeland, Steven M. Paul
-
Patent number: 6566061Abstract: Nucleic acid sequences within the q13 region of the X chromosome having polymorphisms associated with neuropsychiatric disorders and associated conditions are disclosed herein. One polymorphism occurs within the coding region of the HOPA gene and introduces a four amino acid insertion into a putative OPA domain, a domain which has been shown to be involved in tissue specific expression. Compositions including nucleic acids having these polymorphisms and antibodies to polymorphic regions within proteins encoded in the PCTG4 region are provided. Methods of using the information and nucleic acid sequences disclosed herein for the diagnosis and assessment of pathologies associated with neuropsychiatric disorders and associated conditions are also provided.Type: GrantFiled: January 26, 2000Date of Patent: May 20, 2003Assignees: The University of Iowa, as represented by the University of Iowa Research Foundation, The United States of America as represented by the Department of Health and Human ServicesInventors: Robert A. Philibert, Edward I. Ginns, Lynn Delisi
-
Publication number: 20030013178Abstract: The present invention provides the discovery and isolation of the nucleotide sequence of the human clk2, the human propin1, and the human cote1 genes that are located within the glucocerebrosidase gene locus. Also provided by the present invention are proteins or polypeptides encoded by those genes, nucleic acids encoding those polypeptides, and antibodies to those proteins. Further provided by the present invention are nucleic acids of the same apparent molecular size as the propin1 and cote1 gene regions and which have the same restriction pattern as the wild-type genes.Type: ApplicationFiled: February 22, 2001Publication date: January 16, 2003Applicant: Department of Health and Human Sevices, c/o National Institutes of HealthInventors: Edward I. Ginns, Ellen Sidransky, Suzanne L. Winfield, Nahid Tayebi, Brian M. Martin
-
Publication number: 20020192655Abstract: Chromosomal regions comprising loci associated with susceptibility and resistance to bipolar affective disorder have been identified. Methods and compositions are provided for determining the contribution of these chromosomal regions to bipolar affective disorder in an affected family, for determining in an affected family a genotype associated with increased or decreased susceptibility or resistance to bipolar illness, and for assessing an increased or decreased risk of developing bipolar illness for a tested individual from an affected family.Type: ApplicationFiled: June 13, 2001Publication date: December 19, 2002Inventors: Edward I. Ginns, Janice A. Egeland, Steven M. Paul
-
Patent number: 6074864Abstract: Glucocerebrosidase produced by recombinant methods and having use for treatment of Gaucher's disease is disclosed. A cDNA for encoding the specific protein is taught along with the method of preparing the construct used to produce the protein.Type: GrantFiled: January 13, 1994Date of Patent: June 13, 2000Assignee: The United States of America as represented by the Department of Health and Human ServicesInventors: Edward I. Ginns, Brian Martin, Kara A. Maysak, William K. Eliason, Mary E. LaMarca